Sanofi Could Announce Genzyme Deal Next Week

French drugmaker Sanofi-Aventis could announce a deal to buy U.S. biotech Genzyme early next week if final negotiations between the companies go smoothly, Le Figaro reported on Thursday.

Sanofi will offer a minimum of $72 or $73 a share in cash, as well as a contingent value right (CVR) based on the performance of experimental multiple sclerosis drug Lemtrada worth between $2 and $5 a share, the newspaper said.

Genzyme has rejected Sanofi's initial $18.5 billion offer, worth $69 a share, which the French group has extended until Feb. 15.

Sanofi this week gained access to detailed financial information about Genzyme as the two agreed in principle on the terms of a takeover, raising expectations that a final deal can be hammered out in the near term.

Sanofi has agreed to raise its bid to the low $70s-per-share range, plus the CVR milestone payment, a source familiar with the situation said earlier this week, but it did not raise the offer as high as the $75 per share value Genzyme had sought.

The final valuation could be in the "very high $70s" including the CVR, a second source said.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.